Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Disparities in Hepatocellular Carcinoma Incidence in California: An Update.

Sangaramoorthy M, Yang J, DeRouen MC, Ho C, Somsouk M, Tana MM, Thompson CA, Gibbons J, Gomez SL, Shariff-Marco S.

Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):79-87. doi: 10.1158/1055-9965.EPI-19-0560. Epub 2019 Nov 12.

PMID:
31719066
2.

Fatigued Patients with Chronic Liver Disease Have Subtle Aberrations of Sleep, Melatonin and Cortisol Circadian Rhythms.

Tana MM, Alao H, Morris N, Bernstein S, Hattenbach J, Rehman RB, Brychta R, Sarkar S, Zhao X, Walter M, Buckley A, Chen K, Rotman Y.

Fatigue. 2018;6(1):5-19. doi: 10.1080/21641846.2018.1408539. Epub 2017 Dec 3.

3.

Race/ethnicity is an independent risk factor for autoimmune hepatitis among the San Francisco underserved.

Lee B, Holt EW, Wong RJ, Sewell JL, Somsouk M, Khalili M, Maher JJ, Tana MM.

Autoimmunity. 2018 Aug;51(5):258-264. doi: 10.1080/08916934.2018.1482884. Epub 2018 Jun 11.

4.

Hospitalizations for Autoimmune Hepatitis Disproportionately Affect Black and Latino Americans.

Wen JW, Kohn MA, Wong R, Somsouk M, Khalili M, Maher J, Tana MM.

Am J Gastroenterol. 2018 Feb;113(2):243-253. doi: 10.1038/ajg.2017.456. Epub 2018 Jan 30.

5.

Diagnosing Liver Fibrosis and Cirrhosis: Serum, Imaging, or Tissue?

Tana MM, Muir AJ.

Clin Gastroenterol Hepatol. 2018 Jan;16(1):16-18. doi: 10.1016/j.cgh.2017.06.050. Epub 2017 Jul 8. No abstract available.

PMID:
28694131
6.

A comparison of methods for evaluation of a case of suspected macro-aspartate aminotransferase.

van Wijk XMR, Magee CA, Wu AHB, Tana MM, Lynch KL.

Clin Chim Acta. 2016 Dec 1;463:1-3. doi: 10.1016/j.cca.2016.10.011. Epub 2016 Oct 11.

PMID:
27732874
7.

Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States.

Ha J, Yan M, Aguilar M, Bhuket T, Tana MM, Liu B, Gish RG, Wong RJ.

Cancer. 2016 Aug 15;122(16):2512-23. doi: 10.1002/cncr.30103. Epub 2016 May 19.

8.

The Significance of Autoantibody Changes Over Time in Primary Biliary Cirrhosis.

Tana MM, Shums Z, Milo J, Norman GL, Leung PS, Gershwin ME, Noureddin M, Kleiner DE, Zhao X, Heller T, Hoofnagle JH.

Am J Clin Pathol. 2015 Oct;144(4):601-6. doi: 10.1309/AJCPQV4A7QAEEFEV.

9.

Factors associated with the platelet count in patients with chronic hepatitis C.

Tana MM, Zhao X, Bradshaw A, Moon MS, Page S, Turner T, Rivera E, Kleiner DE, Heller T.

Thromb Res. 2015 May;135(5):823-8. doi: 10.1016/j.thromres.2015.02.010. Epub 2015 Feb 19.

10.

Hepatitis B virus treatment: Management of antiviral drug resistance.

Tana MM, Ghany MG.

Clin Liver Dis (Hoboken). 2013 Mar 1;2(1):24-28. doi: 10.1002/cld.162. eCollection 2013 Feb. Review. No abstract available.

11.

Autoantibodies in hepatitis C: red flag or bystander effect?

Tana MM, Heller T.

J Pediatr Gastroenterol Nutr. 2013 Mar;56(3):243. doi: 10.1097/MPG.0b013e3182774b04. No abstract available.

12.

Scar undone: long-term therapy of hepatitis B.

Tana MM, Hoofnagle JH.

Lancet. 2013 Feb 9;381(9865):433-4. doi: 10.1016/S0140-6736(12)61721-8. Epub 2012 Dec 10. No abstract available.

PMID:
23234726

Supplemental Content

Support Center